Key Points
- Progyny CFO Mark Livingston sold 8,275 shares on May 20 at an average price of $25.50, totaling $211,012.50. After the sale, he still owned 79,063 shares, and the move was made under a pre-arranged Rule 10b5-1 trading plan.
- Progyny recently reported stronger-than-expected quarterly results, posting EPS of $0.29 versus consensus of $0.26 and revenue of $328.5 million, slightly above estimates. However, revenue was still down 26.4% from the same quarter a year ago.
- Analysts remain broadly positive on PGNY, with a consensus rating of “Moderate Buy” and an average price target of $29.55. Several firms recently reaffirmed or upgraded their ratings, including Jefferies, Citigroup, and Zacks Research.
Progyny, Inc. (NASDAQ:PGNY - Get Free Report) CFO Mark Livingston sold 8,275 shares of the business's stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $25.50, for a total transaction of $211,012.50. Following the completion of the transaction, the chief financial officer owned 79,063 shares in the company, valued at approximately $2,016,106.50. This trade represents a 9.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Progyny Trading Down 3.7%
Shares of Progyny stock opened at $24.69 on Friday. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of 32.06, a P/E/G ratio of 1.36 and a beta of 0.91. The firm's 50-day moving average price is $18.92 and its two-hundred day moving average price is $22.01. Progyny, Inc. has a 1-year low of $16.10 and a 1-year high of $28.75.
Progyny (NASDAQ:PGNY - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.26 by $0.03. The company had revenue of $328.50 million during the quarter, compared to analysts' expectations of $326.47 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. Progyny's quarterly revenue was down 26.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, equities research analysts predict that Progyny, Inc. will post 1.12 EPS for the current year.
Hedge Funds Weigh In On Progyny
Hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its position in Progyny by 384.8% in the first quarter. Royal Bank of Canada now owns 13,027 shares of the company's stock worth $291,000 after purchasing an additional 10,340 shares during the period. Amundi lifted its position in Progyny by 103.8% during the 1st quarter. Amundi now owns 11,419 shares of the company's stock valued at $264,000 after purchasing an additional 5,817 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Progyny by 6.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company's stock valued at $5,630,000 after purchasing an additional 14,297 shares during the period. Invesco Ltd. boosted its stake in shares of Progyny by 37.4% in the 2nd quarter. Invesco Ltd. now owns 379,189 shares of the company's stock valued at $8,342,000 after purchasing an additional 103,253 shares during the last quarter. Finally, Walleye Capital LLC boosted its stake in shares of Progyny by 6.9% in the 2nd quarter. Walleye Capital LLC now owns 12,080 shares of the company's stock valued at $266,000 after purchasing an additional 780 shares during the last quarter. Institutional investors own 94.93% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have commented on the company. Jefferies Financial Group reissued a "buy" rating and issued a $30.00 price objective on shares of Progyny in a research note on Friday, March 6th. Citigroup restated an "outperform" rating on shares of Progyny in a research note on Monday, May 11th. Wall Street Zen raised Progyny from a "hold" rating to a "buy" rating in a report on Saturday, April 18th. Zacks Research upgraded shares of Progyny from a "hold" rating to a "strong-buy" rating in a research report on Thursday, May 7th. Finally, Citizens Jmp increased their price objective on shares of Progyny from $30.00 to $31.00 and gave the stock a "market outperform" rating in a report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $29.55.
Check Out Our Latest Analysis on PGNY
Progyny Company Profile
(
Get Free Report)
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
